Survival of patients with advanced melanoma according to first-line treatment and key prognostic factors: Real-world data from GEM1801 study

Simple item page
dc.conference.dateSEP 16-21, 2021
dc.conference.titleCongress of the European-Society-for-Medical-Oncology (ESMO)
dc.contributor.authorMarquez-Rodas, I.
dc.contributor.authorBerciano Guerrero, M. A.
dc.contributor.authorMunoz Couselo, E.
dc.contributor.authorManzano, J. L.
dc.contributor.authorCrespo Herrero, G.
dc.contributor.authorSoria, A.
dc.contributor.authorCerezuela, P.
dc.contributor.authorPuertolas Hernandez, T.
dc.contributor.authorBerrocal, A.
dc.contributor.authorMajem Tarruella, M.
dc.contributor.authorBellido Hernandez, L.
dc.contributor.authorEspinosa, E.
dc.contributor.authorGarcia Castano, A.
dc.contributor.authorMedina Martinez, J.
dc.contributor.authorFernandez Morales, L. A.
dc.contributor.authorAguado de la Rosa, C.
dc.contributor.authorGutierrez Sanz, L.
dc.contributor.authorLopez Castro, R.
dc.contributor.authorAyala de Miguel, P.
dc.contributor.authorMartin Algarra, S.
dc.contributor.authoraffiliation[Marquez-Rodas, I.] Hosp Gen Univ Gregorio Maranon, Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Berciano Guerrero, M. A.] HURyVV Hosp Univ Reg & Virgen Victoria Malaga, IBIMA Inst Invest Biomed Malaga, Unidad Intercentros Oncol, Oncol Dept, Malaga, Spain
dc.contributor.authoraffiliation[Munoz Couselo, E.] Vall dHebron Inst Oncol, Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Manzano, J. L.] H Germans Trias & Pujol, Med Oncol, ICO Badalona, Barcelona, Spain
dc.contributor.authoraffiliation[Crespo Herrero, G.] Hosp Univ Burgos, Med Oncol, Burgos, Spain
dc.contributor.authoraffiliation[Soria, A.] Hosp Univ Ramon y Cajal, Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Cerezuela, P.] Hosp Virgen Arrixaca, Med Oncol, Murcia, Spain
dc.contributor.authoraffiliation[Puertolas Hernandez, T.] Hosp Miguel Servet, Med Oncol Dept, Zaragoza, Spain
dc.contributor.authoraffiliation[Berrocal, A.] Hosp Gen Univ Valencia, Med Oncol, Valencia, Spain
dc.contributor.authoraffiliation[Majem Tarruella, M.] Hosp Santa Creu & Sant Pau, Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Bellido Hernandez, L.] Complejo Asistencial Univ Salamanca, Med Oncol, Salamanca, Spain
dc.contributor.authoraffiliation[Espinosa, E.] Hosp Univ La Paz, Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Garcia Castano, A.] Hosp Univ Marques Valdecilla, Med Oncol, Santander, Spain
dc.contributor.authoraffiliation[Medina Martinez, J.] Hosp Virgen Salud, Med Oncol, Toledo, Spain
dc.contributor.authoraffiliation[Fernandez Morales, L. A.] Parc Tauli Univ Hosp, Med Oncol, Sabadell, Spain
dc.contributor.authoraffiliation[Aguado de la Rosa, C.] Hosp Clin San Carlos, Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Gutierrez Sanz, L.] Hosp Univ Puerta Hierro, Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Lopez Castro, R.] Hosp Clin Univ Valladolid, Med Oncol, Valladolid, Spain
dc.contributor.authoraffiliation[Ayala de Miguel, P.] Univ Hosp San Pedro Alcantara, Med Oncol, Caceres, Spain
dc.contributor.authoraffiliation[Martin Algarra, S.] Clin Univ Navarra, Oncol Dept, Pamplona, Spain
dc.contributor.funderNovartis
dc.contributor.funderPierre Fabre
dc.contributor.funderRoche
dc.contributor.funderIncyte
dc.contributor.funderBMS
dc.contributor.funderMSD
dc.date.accessioned2025-01-07T15:15:42Z
dc.date.available2025-01-07T15:15:42Z
dc.date.issued2021-09-21
dc.identifier.doi10.1016/j.annonc.2021.08.1441
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.annonc.2021.08.1441
dc.identifier.urihttps://hdl.handle.net/10668/26995
dc.identifier.wosID700527702074
dc.issue.number5
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen de la Victoria
dc.organizationSAS - Hospital Universitario Regional de Málaga
dc.organizationInstituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
dc.page.numberS881-S882
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleSurvival of patients with advanced melanoma according to first-line treatment and key prognostic factors: Real-world data from GEM1801 study
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number32
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen de la Victoria
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)
Instituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía